WHO ICTRP trial
A study of enfortumab vedotin alone or in combination with other anticancer…
EUCTR2018-001527-39-FR · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2018-001527-39-FR |
|---|---|
| Public title | A study of enfortumab vedotin alone or in combination with other anticancer therapies for the treatment of urothelial cancer |
| Scientific title | A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer |
| Primary sponsor | Seagen Inc. |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): no |
| Countries | Canada;United States;Italy;France;Spain |
| Conditions | Urothelial cancer MedDRA version: 20.0 Level: LLT Classification code 10046714 Term: Urothelial carcinoma bladder System Organ Class: 100000004864 MedDRA version: 20.0 Level: LLT Classification code 10046723 Term: Urothelial carcinoma… |
| Interventions | Trade Name: PADCEV Product Name: Enfortumab vedotin Product Code: ASG-22CE Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: ENFORTUMAB VEDOTIN Current Sponsor code: ASG-22CE Concentration unit… |
| Registration date | Apr 2, 2021 |
| Target size | 150 |
| Secondary IDs | SGN22E-002 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: